Ang1-Expressing Stem Cells via Culture Medium

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current stem cell therapies for ischemic heart disease are limited by insufficient expression of angiogenic factors, particularly Ang1, in many types of stem cells, and genetic modification techniques are complex and may have undesirable effects.

Innovation Solution

The production of genetically unmodified stem cells that express high levels of Ang1, potentially combined with low levels of VEGF, without the need for transfection, using specific cell culture media conditions that include a short acting L-ascorbic acid derivative and reduced fetal calf serum.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If stem cells are genetically modified to overexpress Ang1, then Ang1 expression level is improved, but device complexity and safety risks worsen

Engineering Contradiction:

ImproveAng1 expression levelVSAvoidgenetic modification complexity

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent changes the culture medium parameters (adding bFGF and HGF at specific concentrations, controlling serum levels) to induce high Ang1 expression in unmodified stem cells, avoiding genetic modification while achieving the desired protein expression level

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The stem cells themselves produce high levels of Ang1 through controlled culture conditions without external genetic intervention, allowing the cells to naturally express the angiogenic factor at therapeutic levels

Inventive Principle:

Principle #25Self-service

2Quantity of substance

If genetically modified stem cells are used, then Ang1 expression is improved, but reliability and safety worsen due to potential undesirable effects

Engineering Contradiction:

ImproveAng1 expression levelVSAvoidsafety of stem cell therapy

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent converts the limitation of natural low Ang1 expression into a benefit by using specific growth factors (bFGF and HGF) in the culture medium to induce high Ang1 production, turning a weakness into a therapeutic strength without safety risks

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The culture medium components (bFGF and HGF) act as intermediaries to stimulate stem cells to produce Ang1, providing an indirect method to achieve high Ang1 expression without direct genetic modification of the cells

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of manufacture

If conventional stem cell therapy is used, then treatment simplicity is maintained, but Ang1 expression level remains insufficient

Engineering Contradiction:

Improvesimplicity of stem cell preparationVSAvoidAng1 expression level

Core Design Contradiction:

Ease of manufactureVSQuantity of substance

Solution Approach 1:

By modifying culture medium parameters (adding bFGF 10-100 ng/mL and HGF 10-100 ng/mL, controlling serum concentration), the patent achieves high Ang1 expression while maintaining relatively simple culture procedures

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The culture medium formulation serves multiple functions: maintaining stem cell viability, inducing high Ang1 expression, and controlling the Ang1:VEGF ratio, making it a multi-functional solution that addresses several requirements simultaneously

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250136944A1Stem cell composition

Publication Date: 2025.05.01 MESOBLAST INTERNATIONAL SARL

AI summary

The disclosure provides stem cells which express high levels of Angeopoetin-1 (Ang1) and methods for their production. Such stem cells may be used in a range of therapeutic applications.